Validation of an ICD-9–based claims algorithm for identifying patients with chronic idiopathic/spontaneous urticaria

Cherepanov, Dasha; Raimundo, Karina; Chang, Eunice; Eagan, Marianne; Zazzali, James L.; Solari, Paul G.; DeCotiis, Bruce A.; Hussaın, Iftikhar; Rehman, Syed M.; Shahab, N; Tilles, Stephen A.; Broder, Michael S.

doi:10.1016/j.anai.2015.02.003

Cited by 24 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median duration of CU in the present study population was 1.6 years, which is similar to previous reports 1920. Over a 5-year period, only 12% of CU patients stopped visiting clinics within 3 months in our study; the highest proportion of patients was treated for 12-24 months, accounting for 23% of all patients with CU.…”

Section: Discussionsupporting

confidence: 89%

Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014

Lee

et al. 2017

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

PurposeThere are very few epidemiological studies on chronic urticaria (CU). We aimed to investigate the prevalence of CU and to depict demographics and medication patterns for the disease in a nationwide population-based study.MethodsData on urticaria (L50 of the International Classification of Diseases, 10th revision) from 2010 to 2014 were obtained from the Korean Health Insurance Review and Assessment Service. Algorithms designed to evaluate prescription drug claims for antihistamines were applied to identify CU.ResultsThe crude prevalence of CU was 2,256.5 per 100,000 person-years and tended to increase every year. The age-standardized prevalence of CU was significantly higher in females than in males (2,466.8 vs 1,819.2 per 100,000 person-years, P<0.001). Age-specific prevalence was highest for older adults over the age of 65 years and lowest for ages 10-29 years. The median duration of CU was 591 days, and symptoms lasted for at least 1 year in 61.9% of patients. Gastrointestinal disease was the most common comorbidity in adults, whereas allergic rhinitis and common cold were more prevalent in children with CU. Around a third of CU patients were taking antihistamine treatment alone, and 70% were treated with both antihistamines and systemic corticosteroids. Cyclosporine was prescribed for 0.02% of CU patients.ConclusionsThe present study outlines recent longitudinal epidemiological data on the prevalence of CU in Korea. In light of limitations on the use of claims data, including no specific disease code for CU and a possible discordance between drug claims and the presence of urticaria symptoms, further investigations are necessary to describe the exact epidemiologic profile of CU patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014

Lee

et al. 2017

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

show abstract

“…In order to overcome this limitation, we adopted a modified version of the algorithm previously used by Zazzali et al . to identify cases of CIU/CSU through the ICD‐9‐CM classification and medication use, and subsequently tested by Cherepanov et al . by reviewing medical charts.…”

Section: Methodsmentioning

confidence: 99%

Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy

Lapi

Cassano²,

Pégoraro³

et al. 2016

Br J Dermatol

132

112

View full text Add to dashboard Cite

show abstract

“…To be included in the study, the patients were required to have CIU/CSU identified based on the validated algorithm 17 : two or more independent claims with a diagnosis for idiopathic ( ; ICD-10-CM code L50.9xx) Ն6 weeks apart or one or more claims with a diagnosis for idiopathic, other, or unspecified urticaria; and one or more claims with a diagnosis for angioedema (ICD-9-CM code 995.1x; ICD-10-CM code T78.3) Ն6 weeks apart. In addition, the patients were required to have one or more pharmacy or medical claims of omalizumab, with the first claim being after March 21, 2014.…”

Section: Methodsmentioning

confidence: 99%

Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States

Eghrari-Sabet¹,

Sher²,

Kavati

et al. 2018

allergy asthma proc

View full text Add to dashboard Cite

show abstract

Validation of an ICD-9–based claims algorithm for identifying patients with chronic idiopathic/spontaneous urticaria

Cited by 24 publications

References 18 publications

Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014

Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014

Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy

Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States

Contact Info

Product

Resources

About